Market Research Report - 245537
Clinical trials in Central Europe 2012: Development forecasts for 2012-2014
|Published||Content info||193 Pages|
|Clinical trials in Central Europe 2012: Development forecasts for 2012-2014|
|Published: April 30, 2012||Content info: 193 Pages||
The report analyses the environment for conducting clinical trials in Poland, Hungary, the Czech Republic, Romania, Slovakia and Bulgaria. It presents key information regarding market size in terms of the number of clinical trials and size of market share of the largest sponsors.
It also covers the most influential trends and circumstances affecting the sector and present-day market value, along with forecasts for 2012-2014 based on the number of newly registered clinical trials. It contains detailed coverage of current and anticipated market conditions, opportunities and obstacles to overall market growth, length of the average registration time for clinical trials, attributes and market standing of the major companies conducting clinical trials, the largest players (sponsors and CROs, their activity in the area of clinical trials, with special attention given to the number of trials, location, and therapeutic areas).
The report also features a comparative analysis of market, governmental and regulatory conditions governing the conduct of clinical trials in the analysed CE countries.
This region is very attractive to pharmaceutical companies and there are many conferences and a great deal of activity and interest in the subject of clinical trials. Companies are searching urgently for new areas in which to establish and conduct trials, as in the developed countries, the recruitment rate is very slow. Timing is important, since companies are now under increasing pressure to develop new therapies as patents on many blockbuster drugs have expired or will expire in the near future.
" Comparative analysis of conditions under which clinical trials are conducted in CE Legal aspects of the sector, including information on the upcoming legislative modifications that are relevant to the conduct of Clinical Trials Detailed profiles of the largest CROs and trial sponsors active in the region.
With unique coverage and analysis of market conditions in each of the covered countries, careful analysis of relationships between trends and results, solid, explanatory forecasts and in depth profiles of the market's most experienced and successful players, this comprehensive report surpasses all competition in terms of value.
Roche, Pfizer, Novartis, GlaxoSmithKline, Eli Lilly, Bristol-Myers Squibb, AstraZeneca, Johnson and Johnson, Boehringer Ingelheim, Amgen, Total, Quintiles, Covance, Icon, Parexel, Premier Research, INC Research, PRA, PPD, PSI, Monipol.
In the area of clinical trials, the Central European region provides unique advantages to international pharmaceutical concerns: the associated costs of trials remain relatively low, it is easier to find appropriate candidates to participate in a clinical trial, as candidates are more interested in participation due to lack of money and limited reimbursement. The region analysed still participates in a centralised healthcare system, which means that its countries contain large hospitals that specialise in oncology, cardiology and rheumatology, which rank among the most popular therapeutic categories for clinical trials. Worthy of note, however, are the drawbacks and barriers described by the report as they represent crucial knowledge for any company conducting (or intending to commence) clinical trials in the six countries analysed in the publication.
Monika Stefańczyk, Head Pharmaceutical market Analyst